|
1
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosch FX, Ribes J, Diaz M and Cleries R:
Primary livercancer: Worldwide incidence and trends.
Gastroenterology. 127 5 Suppl 1:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carlomagno F, Anaganti S, Guida T,
Salvatore G, Troncone G, Wilhelm SM and Santoro M: BAY 43–9006
inhibition of oncogenic RET mutants. J Natl Cancer Inst.
98:326–334. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang YS, Adnane J, Trail PA, Levy J,
Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A,
et al: Sorafenib (BAY 43–9006) inhibits tumor growth and
vascularization and induces tumor apoptosis and hypoxia in RCC
xenograft models. Cancer Chemother Pharmacol. 59:561–574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP investigators study group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qi F, Li A, Inagaki Y, Kokudo N, Tamura S,
Nakata M and Tang W: Antitumor activity of extracts and compounds
from the skin of the toad Bufo bufo gargarizans Cantor. Int
Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: Bufalin induces growth inhibition, cell cycle arrest
and apoptosis in human endometrial and ovarian cancer cells. Int J
Mol Med. 21:637–643. 2008.PubMed/NCBI
|
|
9
|
Huang WW, Yang JS, Pai SJ, Wu PP, Chang
SJ, Chueh FS, Fan MJ, Chiou SM, Kuo HM, Yeh CC, et al: Bufalin
induces G0/G1 phase arrest through inhibiting the levels of cyclin
D, cyclin E, CDK2 and CDK4 and triggers apoptosis via mitochondrial
signaling pathway in T24 human bladder cancer cells. Mutat Res.
732:26–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin JQ, Shen JN, Su WW, Wang J, Huang G,
Jin S, Guo QC, Zou CY, Li HM and Li FB: Bufalin induces apoptosis
in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant
cell lines. Acta Pharmacol Sin. 28:712–720. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Efferth T, Davey M, Olbrich A, Rücker G,
Gebhart E and Davey R: Activity of drugs from traditional Chinese
medicine toward sensitive and MDR1- or MRP1-overexpressing
multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol
Dis. 28:160–168. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Zhang C, Ning Z, Xu L, Zhu X and
Meng Z: Bufalin enhances anti-angiogenic effect of sorafenib via
AKT/VEGF signaling. Int J Oncol. 48:1229–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang H, Zhang C, Xu L, Zang K, Ning Z,
Jiang F, Chi H, Zhu X and Meng Z: Bufalin suppresses hepatocellular
carcinoma invasion and metastasis by targeting HIF-1α via the
PI3K/AKT/mTOR pathway. Oncotarget. 7:20193–20208. 2016.PubMed/NCBI
|
|
14
|
Chen S, Wang G, Niu X, Zhao J, Tan W, Wang
H, Zhao L and Ge Y: Combination of AZD2281 (Olaparib) and GX15-070
(Obatoclax) results in synergistic antitumor activities in
preclinical models of pancreatic cancer. Cancer Lett. 348:20–28.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Cui X, Qu L, Hua L, Wu M, Shen Z,
Lu C and Ni R: Overexpression of DLX2 is associated with poor
prognosis and sorafenib resistance in hepatocellular carcinoma. Exp
Mol Pathol. 101:58–65. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Chen C, Wang S, Zhang Y, Yin P,
Gao Z, Xu J, Feng D, Zuo Q, Zhao R and Chen T: Bufalin inhibits
HCT116 colon cancer cells and its orthotopic xenograft tumor in
mice model through genes related to apoptotic and PTEN/AKT
pathways. Gastroenterol Res Pract. 2015:4571932015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang
T, Pan S, Sun X and Xu L: Bufalin reverses resistance to sorafenib
by inhibiting Akt activation in hepatocellular carcinoma: The role
of endoplasmic reticulum stress. PLoS One. 10:e01384852015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hajra KM and Liu JR: Apoptosome
dysfunction in human cancer. Apoptosis. 9:691–704. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghavami S, Hashemi M, Ande SR, Yeganeh B,
Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, et
al: Apoptosis and cancer: Mutations within caspase genes. J Med
Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He GW, Günther C, Thonn V, Yu YQ, Martini
E, Buchen B, Neurath MF, Stürzl M and Becker C: Regression of
apoptosis-resistant colorectal tumors by induction of necroptosis
in mice. J Exp Med. 214:1655–1662. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ucker DS and Levine JS: Exploitation of
apoptotic regulation in cancer. Front Immunol. 9:2412018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Green DR: Apoptotic pathways: Ten min to
dead. Cell. 121:671–674. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kwon KB, Park BH and Ryu DG: Chemotherapy
through mitochondrial apoptosis using nutritional supplements and
herbs: A brief overview. J Bioenerg Biomembr. 39:31–34. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke
AW, Wang XY, Dai Z, Peng YF, Gu CY, et al: Targeting autophagy
enhances sorafenib lethality for hepatocellular carcinoma via ER
stress-related apoptosis. Autophagy. 7:1159–1172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fadeel B and Orrenius S: Apoptosis: A
basic biological phenomenon with wide-ranging implications in human
disease. J Intern Med. 258:479–517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ly JD, Grubb DR and Lawen A: The
mitochondrial membrane potential (deltapsi (m)) in apoptosis; an
update. Apoptosis. 8:115–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ji BC, Hsu WH, Yang JS, Hsia TC, Lu CC,
Chiang JH, Yang JL, Lin CH, Lin JJ, Suen LJ, et al: Gallic acid
induces apoptosis via caspase-3 and mitochondrion-dependent
pathways in vitro and suppresses lung xenograft tumor growth in
vivo. J Agric Food Chem. 57:7596–7604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Logue SE and Martin SJ: Caspase activation
cascades in apoptosis. Biochem Soc Trans. 36:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang Z, Takahashi Y, Chen C, Liu Y, He H,
Tsotakos N, Serfass JM, Gebru MT, Chen H, Young MM and Wang HG:
Atg2A/B deficiency switches cytoprotective autophagy to
non-canonical caspase-8 activation and apoptosis. Cell Death
Differ. 24:2127–2138. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Concha NO and Abdel-Meguid SS: Controlling
apoptosis by inhibition of caspases. Curr Med Chem. 9:713–726.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng Q, Wang B, Gao J, Xin N, Wang W,
Song X, Shao Y and Zhao C: CD155 knockdown promotes apoptosis via
AKT/Bcl-2/Bax in colon cancer cells. J Cell Mol Med. 22:131–140.
2018. View Article : Google Scholar : PubMed/NCBI
|
